Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway
John D. Groarke, Toni K. Choueiri, David Slosky et al. · Current Treatment Options in Cardiovascular Medicine · 2014
Cited by 41 works. doi:10.1007/s11936-014-0335-0
Authors
References
- 2013 ACCF/AHA Guideline for the Management of Heart Failure
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
- The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma